CN1543978A - Highly concentration water-soluble vitamin for intravenous injection and preparation and use - Google Patents
Highly concentration water-soluble vitamin for intravenous injection and preparation and use Download PDFInfo
- Publication number
- CN1543978A CN1543978A CNA2004100057788A CN200410005778A CN1543978A CN 1543978 A CN1543978 A CN 1543978A CN A2004100057788 A CNA2004100057788 A CN A2004100057788A CN 200410005778 A CN200410005778 A CN 200410005778A CN 1543978 A CN1543978 A CN 1543978A
- Authority
- CN
- China
- Prior art keywords
- water soluble
- soluble vitamins
- vitamin
- injection
- intravenous injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a high-concentration-type water soluble vitamin used for intravenous injections, with each bottle containing 6.2 +-1.6 mg aneurine mononitrate, 9.8+-2.5 mg lactoflavin sodium phosphate, 80+-20 mg nicotinic amide, 9.8+-2.5 mg phosphopyridoxamine, 33.0+-8.3 mg panthoject, 200+-50 mg vitamin, 120 +-30 mu g biotin, 0.8+-0.2 mg acidum folicum, 10.0+-2.5 mu g vitamin B12 and 1-6ml water for injection. The preparing method is as follows: stirring the components mentioned above with water for injection until they are entirety dissolved, freezing-drying them in a freezing-drying machine, pressing them to prepare the water soluble vitamins used for intravenous injection. The water soluble vitamins used for intravenous injection in accordance with the present invention can be used for guarding against and curing cacotrophia caused by deficiency of water soluble vitamins and for auxiliary cure of chronic diseases such as chronic hepatic disease and the like; the water soluble vitamins used for intravenous injection possesses advantages of rapid vitamin supplying, medicament curative effect enhancement, reduced side-effects and the like, can satisfy clinical require for supplying of serious water soluble vitamins deficiency caused by diseases.
Description
Technical field
The present invention relates to high dense type water soluble vitamins of a kind of used for intravenous injection and its production and use.
Background technology
Water soluble vitamins is that to keep the body normal function necessary, and water soluble vitamins should be taken in a certain amount of for needs every day.At present clinically adopt oral administrations or various water soluble vitamins is individually dosed or the drug administration by injection vitimin supplement more, to store up allowance in vivo very few because of water soluble vitamins, in case surpass then drained rapidly, dosage all improves slightly according to the vitamin daily requirement, does not have the more use of high dose.Under special pathological state, as continuing hyperpyrexia, burn, hepatic injury, major operation etc., to the increase in demand of water soluble vitamins, clinical administration all can't satisfy the additional needs that clinical serious water soluble vitamins lacks at present.
Summary of the invention
The present invention provides high dense type water soluble vitamins of a kind of used for intravenous injection and its production and use at the problems referred to above, the high dense type water soluble vitamins of prepared used for intravenous injection obviously improves than conventional formulation curative effect, is particularly useful for the clinical additional needs that lack because of the serious water soluble vitamins due to the disease.
The inventor is by deep research, find that the comparable conventional formulation of high (dosage) dense type water soluble vitamins obviously improves treatment or adjuvant treatment effect, and do not find the increase of toxic and side effects, no anaphylaxis, hemolytic and blood vessel irritation, especially to clinical because of replenishing of lacking of the serious water soluble vitamins due to the disease more reasonable.
Technical scheme provided by the invention is: the high dense type water soluble vitamins of used for intravenous injection, every bottle contains thiamine mononitrate (VitaminB
1) 6.2 ± 1.6mg, riboflavin sodium phosphate (Vitamin B
2) 9.8 ± 2.5mg, nicotiamide (Nicotinamide) 80 ± 20mg, pyridoxine hydrochloride (Vitamin B
6) 9.8 ± 2.5mg, sodium pantothenate (Sodium Pantothenate) 33.0 ± 8.3mg, vitamin C (Vitamin C) 200 ± 50mg, biotin (Biotin) 120 ± 30ug, folic acid (Folic Acid) 0.8 ± 0.2mg, vitamin B
12(Vitamin B
12) 10.0 ± 2.5ug, water for injection 1～6ml.
The preferred version of the high dense type water soluble vitamins of above-mentioned used for intravenous injection is that every bottle contains thiamine mononitrate 6.2mg, riboflavin sodium phosphate 9.8mg, nicotiamide 80mg, pyridoxine hydrochloride 9.8mg, sodium pantothenate 33.0mg, Catergen 00mg, biotin 120ug, folic acid 0.8mg, vitamin B
1210.0ug, water for injection 1～6ml.
The high dense type water soluble vitamins of above-mentioned used for intravenous injection also contains 0～0.8mg antiseptic, 0.3～0.8mg chelating agent, 0～600mg excipient.
Foregoing preservatives is methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate or sorbitol etc.; Chelating agent is Calcium Disodium Versenate, cyclohexanediamine four sodium acetates, N-hydroxyl diethylamine three acetic acid or diethyl triamine six acetic acid etc.; Excipient is glycine, mannitol, lactose or gelatin hydrolysate.
Above-mentioned water soluble vitamins contains 0～0.8mg methyl parahydroxybenzoate (Methylp-hyerosybenzoate), 0.3～0.6mg Calcium Disodium Versenate (Disodium Ethylenediaminetetraacetate), 0～600mg glycine (Glycine).
The present invention also provides the preparation method of the high dense type water soluble vitamins of above-mentioned injection, to be mixed with aqueous solution with the water for injection dissolving on thiamine mononitrate, riboflavin sodium phosphate, nicotiamide, pyridoxine hydrochloride, sodium pantothenate, vitamin C, biotin, folic acid and the vitamin, be loaded on lyophilizing in freezer dryer in the container after the microporous filter, gland makes the used for intravenous injection water soluble vitamins.
Can add antiseptic, chelating agent and excipient in the aqueous solution of above-mentioned preparation, be loaded on lyophilizing in freezer dryer in the container then after the microporous filter, gland makes the vein water soluble vitamins.
Application when the high dense type water soluble vitamins of above-mentioned used for intravenous injection lacks because of the serious water soluble vitamins due to the disease in preparation in the medicine of vitimin supplement, consumption is intravenous drip every day 1～2 time, each one bottle, add 0.9wt% sodium chloride injection or 5wt% or 10wt% glucose injection iv drip during use.
Testing surface, the comparable conventional formulation of the high dense type water soluble vitamins of used for intravenous injection of the present invention obviously improves treatment or adjuvant treatment effect, and do not find the increase of toxic and side effects, no anaphylaxis, hemolytic and blood vessel irritation, especially to clinical because of replenishing of lacking of the serious water soluble vitamins due to the disease more reasonable.It is quick that used for intravenous injection water soluble vitamins of the present invention has vitimin supplement, and medicament curative effect enhancement reduces advantages such as side effect, especially can satisfy the clinical additional needs that lack because of the serious water soluble vitamins due to the disease.Experiment shows, the high dense type water soluble vitamins of used for intravenous injection of the present invention according to dosage uses not only and has no side effect, and vitimin supplement rapidly, and raising has remarkable result to the resistance and the immunity of disease.
The specific embodiment
The present invention is described further by following examples
Embodiment 1: with 1.86g thiamine mononitrate, 2.94g riboflavin sodium phosphate, 24.0g nicotiamide, 2.94g pyridoxine hydrochloride, 9.9g sodium pantothenate, 60.0g vitamin C, 36mg biotin, 0.24g folic acid, 3.0mg vitamin B
12, 0.15g methyl parahydroxybenzoate, 0.15g Calcium Disodium Versenate, 90g glycine dissolve with water for injection, add the injection water and transfer to 900ml, 0.22 μ g filtering with microporous membrane, be distributed into every bottle of 3ml, lyophilization in freezer dryer, gland promptly get the high dense type water soluble vitamins lyophilized injectable powder of required used for intravenous injection.
Embodiment 2: with 1.86g thiamine mononitrate, 2.94g riboflavin sodium phosphate, 24.0g nicotiamide, 2.94g pyridoxine hydrochloride, 9.9g sodium pantothenate, 60.0g vitamin C, 36mg biotin, 0.24g folic acid, 3.0mg vitamin B
12, the 90mg Calcium Disodium Versenate is with the dissolving of 300ml water for injection, 0.22 μ g filtering with microporous membrane is distributed into 300 bottles, lyophilization in freeze dryer, gland promptly get the dense type water soluble vitamins lyophilized injectable powder of required used for intravenous injection height.
Embodiment 3: with 1.42g thiamine mononitrate, 3.60g riboflavin sodium phosphate, 27.3g nicotiamide, 2.28g pyridoxine hydrochloride, 7.63g sodium pantothenate, 53.0g vitamin C, 42mg biotin, 0.20g folic acid, 2.4mg vitamin B
12, the 90mg Calcium Disodium Versenate is with water for injection 300ml dissolving, 0.22 μ g filtering with microporous membrane is distributed into 300 bottles, lyophilization in freeze dryer, gland promptly get the dense type water soluble vitamins lyophilized injectable powder of required used for intravenous injection height.
Embodiment 4: with 2.30g thiamine mononitrate, 2.22g riboflavin sodium phosphate, 20.0g nicotiamide, 3.03g pyridoxine hydrochloride, 9.9g sodium pantothenate, 70.0g vitamin C, 30mg biotin, 0.27g folic acid, 3.6mg vitamin B
12, glycine 180g, sorbitol 0.24g, N-hydroxyl diethylamine three acetic acid 0.18g dissolve with water for injection, add the injection water and transfer to 1800ml, 0.22 μ g filtering with microporous membrane, be distributed into every bottle of 6ml, lyophilization in freeze dryer, gland promptly get the high dense type water soluble vitamins lyophilized injectable powder of required used for intravenous injection.
Embodiment 5: with 3.10g thiamine mononitrate, 4.90g riboflavin sodium phosphate, 40.00g nicotiamide, 4.90g pyridoxine hydrochloride, 16.50g sodium pantothenate, 100g vitamin C, 60mg biotin, 0.40g folic acid, 5.00mg vitamin B
12, propyl p-hydroxybenzoate 0.20g, cyclohexanediamine four sodium acetate 0.20g, lactose 90g dissolve with water for injection, add the injection water and transfer to 1000ml, 0.22 μ g filtering with microporous membrane, be distributed into every bottle of 2ml, lyophilization in freezer dryer, gland promptly get the high dense type water soluble vitamins lyophilized injectable powder of required used for intravenous injection.
Embodiment 6: with 1.86g thiamine mononitrate, 2.94g riboflavin sodium phosphate, 24.0g nicotiamide, 2.94g pyridoxine hydrochloride, 9.9g sodium pantothenate, 60.0g vitamin C, 36mg biotin, 0.24g folic acid, 3.0mg vitamin B
12, glycine 180g, sorbitol 0.24g, N-hydroxyl diethylamine three acetic acid 0.18g dissolve with water for injection, add the injection water and transfer to 1800ml, 0.22 μ g filtering with microporous membrane, be distributed into every bottle of 6ml, lyophilization in freeze dryer, gland promptly get the high dense type water soluble vitamins lyophilized injectable powder of required used for intravenous injection.
Embodiment 7: with 3.10g thiamine mononitrate, 4.90g riboflavin sodium phosphate, 40.00g nicotiamide, 4.90g pyridoxine hydrochloride, 16.50g sodium pantothenate, 100g vitamin C, 60mg biotin, 0.40g folic acid, 5.00mg vitamin B
12, propyl p-hydroxybenzoate 0.20g, cyclohexanediamine four sodium acetate 0.20g, lactose 90g dissolve with water for injection, add the injection water and transfer to 1000ml, 0.22 μ g filtering with microporous membrane, be distributed into every bottle of 2ml, lyophilization in freezer dryer, gland promptly get the high dense type water soluble vitamins lyophilized injectable powder of required used for intravenous injection.
Embodiment 8: with 1.86g thiamine mononitrate, 2.94g riboflavin sodium phosphate, 24.0g nicotiamide, 2.94g pyridoxine hydrochloride, 9.9g sodium pantothenate, 60.0g vitamin C, 36mg biotin, 0.24g folic acid, 3.0mg vitamin B
12Add the water for injection dissolving, add the injection water and transfer to 600ml, 0.22 μ g filtering with microporous membrane is distributed into every bottle of 2ml, lyophilization in freezer dryer, and gland promptly gets the high dense type water soluble vitamins lyophilized injectable powder of required injection.
The high dense type water soluble vitamins of injection is to carbon tetrachloride hepatic injury mice effect research
Experimental technique: select 100 kunming mices and be divided into 11 groups at random, male and female half and half.Except that normal group, other 9 groups every 3 days sc20%CCL
40.02ml/10g plant fluid.The administration group begins administration in the 3rd modeling after 24 hours, successive administration 15 days.(1) normal control group: ip 10%GS 0.1ml/10g, qd; (2) model group; (3) model+low dosage water soluble vitamins group: 1/6 bottle/kg of modeling ip in mice water soluble vitamins, qd; (4) model+high dose water soluble vitamins group: 1/3 bottle/kg of modeling ip in mice water soluble vitamins (2 times of low dosage water soluble vitamins groups), qd; (5) model+base set: modeling ip in mice diammonium glycyrrhizinate 3mg/kg+ inosine 4mg/kg+VitC40mg/kg; (6) model+low dosage+base set: 1/6 bottle/kg of modeling ip in mice diammonium glycyrrhizinate 3mg/kg+ inosine 4mg/kg+VitC40mg/kg+ water soluble vitamins, qd; (7) model+high dose+base set: 1/3 bottle/kg of modeling ip in mice diammonium glycyrrhizinate 3mg/kg+ inosine 4mg/kg+VitC40mg/kg+ water soluble vitamins, qd; (8) model+low dosage water soluble vitamins (Bid) group: 1/6 bottle/kg of modeling ip in mice water soluble vitamins, Bid; (9) model+high dose water soluble vitamins (Bid) group: 1/3 bottle/kg of modeling ip in mice water soluble vitamins, Bid; (10) model+low dosage+basis (Bid) group: 1/6 bottle/kg of modeling ip in mice diammonium glycyrrhizinate 3mg/kg+ inosine 4mg/kg+VitC40mg/kg+ water soluble vitamins; (11) model+high dose+basis (Bid) group: 1/3 bottle/kg of modeling ip in mice diammonium glycyrrhizinate 3mg/kg+ inosine 4mg/kg+VitC40mg/kg+ water soluble vitamins.
Weigh in every day once, adjust the dosage experiment according to body weight change and measure following index after 15 days:
1. body weight: before the observation experiment and experiment body weight change when finishing.
2. serum glutamic pyruvic transminase (ALT/GPT): when experiment finished, every mice was plucked eyeball and gets blood, measured serum glutamic pyruvic transminase content, method Herba Liparidis nervosae glutamate pyruvate transaminase test kit description with reitman-frankel method.
3. serum total bilirubin: when experiment finished, every mice was plucked eyeball and gets blood, with caffeine colorimetric method for determining serum total bilirubin content, method Herba Liparidis nervosae total bilirubin test kit description.
4. pathologic finding: when experiment finishes, after mice is plucked eyeball and gets blood, get liver immediately, and fix with 4% paraformaldehyde.HE dyeing, microscopically is observed, and takes a picture.
Date processing
Data are represented with x ± S, carry out statistical procedures through variance analysis.
The result
Water soluble vitamins is to the influence of CCl4 hepatic injury mice body weight
Table 1 result as seen, separately use water soluble vitamins once a day, hepatic injury mice weight loss is not had obvious influence, give the water soluble vitamins of Isodose one day twice, can obviously improve the body weight of damage mice, effect of high dosage significantly improves than low dosage; With clinical liver protection treatment scheme commonly used (base set) coupling water soluble vitamins, visible water soluble vitamins can obviously improve the weight of mice value.
Table 1. water soluble vitamins is to the influence of CCl4 hepatic injury mice body weight
Experiment finishes before and after the experiment of back before the sample experiment
Group
Number body weight (g) body weight (g) body weight difference (g)
Normal control group 10 21.1 ± 1.6 28.2 ± 1.0 7.1 ± 1.6
Model group 7 22.7 ± 1.7 21.1 ± 2.5-1.6 ± 1.3**
Model+low dose group 7 22.3 ± 1.5 22.2 ± 1.5-0.1 ± 0.8
Model+high dose group 8 22.4 ± 1.7 22.4 ± 1.8 0 ± 2.4
Model+base set 8 23.4 ± 1.8 24.2 ± 0.9 0.8 ± 1.3
▲ ▲
Model+low dosage+base set 7 22.8 ± 1.1 24.4 ± 1.5 1.6 ± 0.7
▲ ▲ ● ●
Model+high dose+base set 8 23.8 ± 1.1 26.0 ± 1.8 2.2 ± 1.8
▲ ▲ ● ●
Model+low dose group
9 21.6±1.6 22.7±1.4 1.1±1.2
▲▲
(Bid)
Model+high dose group
8 22.1±1.1 23.4±1.5 1.4±0.7
▲▲
(Bid)
Model+low dosage+base set
10 22.6±1.3 23.6±2.4 1.0±1.9
▲▲
(Bid)
Model+high dose+base set
9 23.6±0.9 26.6±1.9 3.0±1.6
▲▲●●
(Bid)
Compare * * p＜0.01 with matched group, compare with model group
▲ ▲P＜0.01 is compared with base set
● ●P＜0.01 water soluble vitamins is to the influence of CCl4 hepatic injury mice serum glutamate pyruvate transaminase, serum total bilirubin
Use water soluble vitamins once a day separately, hepatic injury mice weight loss is not had obvious influence, the low dosage water soluble vitamins does not reduce serum glutamic pyruvic transminase, but can improve serum total bilirubin content, and effect of high dosage is remarkable than low dosage; Twice administration in one day can obviously reduce damage mice serum glutamate pyruvate transaminase and total bilirubin, and effect of high dosage is better than low dosage; With clinical liver protection treatment scheme commonly used (base set) coupling water soluble vitamins; as seen water soluble vitamins can obviously strengthen the protective effect of clinical hepatoprotective scheme commonly used to hepatic injury; reduce serum glutamic pyruvic transminase activity and total bilirubin content, the effect high dose of total bilirubin is better than low dosage.The results are shown in Table 2.
Table 2. water soluble vitamins is to the influence of CCl4 hepatic injury mice serum glutamate pyruvate transaminase, serum total bilirubin
The serum glutamic pyruvic transminase serum total bilirubin
The group sample number
(μmol/ml) (μmol/L)
Normal control group 10 0.401 ± 0.018 123 ± 40
Model group 7 0.750 ± 0.005** 874 ± 149**
Model+low dose group 7 0.721 ± 0.005 735 ± 152
▲ ▲
Model+high dose group 8 0.688 ± 0.038
▲ ▲570 ± 155
▲ ▲
Model+base set 8 0.689 ± 0.006
▲ ▲552 ± 132
▲ ▲
Model+low dosage+base set 7 0.664 ± 0.021
▲ ▲532 ± 118
▲ ▲
Model+high dose+base set 8 0.638 ± 0.010
▲ ▲ ● ●371 ± 123
▲ ▲ ● ●
Model+low dose group
9 0.734±0.010 622±243
(Bid)
Model+high dose group
8 0.672±0.008
▲▲ 516±174
▲▲
(Bid)
Model+low dosage+base set
10 0.652±0.010
▲▲●● 522±143
▲▲
(Bid)
Model+high dose+base set
9 0.650±0.041
▲▲●● 353±145
▲▲●●
(Bid)
Compare * * p＜0.01 with matched group, compare with model group
▲ ▲P＜0.01 is compared with base set
● ●P＜0.01 conclusion
Vitamin H has the certain protection effect to carbon tetrachloride hepatic injury; and can significantly strengthen the therapeutic effect of clinical therapeutic scheme commonly used; high dose (the clinical consumption of the present invention's suggestion) effect is better than low dosage; point out the clinical high dense type water soluble vitamins of injection that adopts to carry out intravenous nutrition, when being used for the auxiliary treatment of multiple disease.
The high dense type water soluble vitamins general pharmacology of injection is learned research
Experimental technique: use the variation that BL-420 biological function experimental system record vein is given the electrocardio of 10%GS, high, medium and low 3 kinds of various dose and normal rat, blood pressure, breathing.Dosage: 10%GS 1ml/200g, 1/6 bottle/kg of low dosage, middle and high dosage are respectively 2,4 times of low dosage.
Get rat and weigh, 20% urethane 5ml/kg ip anesthesia connects electrocardio, and tonotransducer separates common carotid artery, and intubate connects pressure transducer, writes down electrocardio, breathing, blood pressure respectively.The sublingual vein administration, the variation of record These parameters 30 minutes.
Experimental result
The high dense type water soluble vitamins of table 3 injection is to the influence of cardiovascular system
1. blood pressure (mmHg)
2. heart rate (inferior/minute)
3.QRS ripple (mv)
4.ST ripple (mv)
5.T ripple
The high dense type water soluble vitamins of table 4. injection is to the influence of respiratory system
1. frequency (inferior/minute)
2. the degree of depth (g)
Conclusion
High dose does not have influence to rat to the rat general pharmacology, and the dense type water soluble vitamins of prompting injection height of the present invention is applied to clinical safety, reasonable, effective.
The high dense type water soluble vitamins anaphylaxis of injection, hemolytic, blood vessel irritation test
According to " medicine registration management way " (trying) requirement, it has been carried out the safety testing research of systemic administration, result of the test is as follows: dissolve with 10% glucose 500ml, with 0.5ml/ time/ip sensitization three times, 1ml/ iv attacks Cavia porcellus and investigates its systemic anaphylaxis, the result shows that Vitamin H of the present invention can not bring out the obvious anaphylaxis of Cavia porcellus.The hemolytic test method is observed Vitamin H to erythrocytic influence routinely, and the result shows Vitamin H no obvious haemolysis in 4 hours, does not also have hemagglutination.Water soluble vitamins is given rabbit auricular vein intravenous administration for three days on end with the dosage of 10ml/kg, 24 hours perusal injection site situations after the drug withdrawal, and draw materials and carry out histopathologic examination.The result shows that matched group and administration group thrombosis in the blood vessel, hemorrhage and inflammatory cell behind injection point ooze out equal no significant difference.Water breakthrough soluble vitamin group and 10% glucose injection group homomorphosis under the mirror, the rabbit ear vein structural integrity, no vascular endothelial cell swelling, degeneration, necrosis, wall of vein and surrounding tissue thereof do not have inflammatory cell infiltration, and no thrombosis forms in the tube chamber.
Result of the test shows: Vitamin H of the present invention can not cause allergy and hemolytic reaction, does not have blood vessel irritation yet, the clinical intravenous administration that can be used for.
Claims (8)
1. the high dense type water soluble vitamins of a used for intravenous injection, it is characterized in that: every bottle contains thiamine mononitrate 6.2 ± 1.6mg, riboflavin sodium phosphate 9.8 ± 2.5mg, nicotiamide 80 ± 20mg, pyridoxine hydrochloride 9.8 ± 2.5mg, sodium pantothenate 33.0 ± 8.3mg, Catergen 00 ± 50mg, biotin 120 ± 30ug, folic acid 0.8 ± 0.2mg, vitamin B
1210.0 ± 2.5ug, water for injection 1～6ml.
2. vitamin according to claim 1 is characterized in that: every bottle contains thiamine mononitrate 6.2mg, riboflavin sodium phosphate 9.8mg, nicotiamide 80mg, pyridoxine hydrochloride 9.8mg, sodium pantothenate 33.0mg, Catergen 00mg, biotin 120ug, folic acid 0.8mg, vitamin B
1210.0ug, water for injection 1～6ml.
3. vitamin according to claim 1 and 2 is characterized in that: contain 0～0.8mg antiseptic, 0.3～0.8mg chelating agent, 0～600mg excipient.
4. vitamin according to claim 3 is characterized in that: antiseptic is methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate or sorbitol; Chelating agent is Calcium Disodium Versenate, cyclohexanediamine four sodium acetates, N-hydroxyl diethylamine three acetic acid or diethyl triamine six acetic acid; Excipient is glycine, mannitol, lactose or gelatin hydrolysate.
5. vitamin according to claim 1 and 2 is characterized in that: contain 0～0.8mg methyl parahydroxybenzoate, 0.3～0.6mg Calcium Disodium Versenate, 0～600mg glycine.
6. the preparation method of the high dense type water soluble vitamins of the described used for intravenous injection of claim 1, it is characterized in that: thiamine mononitrate, riboflavin sodium phosphate, nicotiamide, pyridoxine hydrochloride, sodium pantothenate, vitamin C, biotin, folic acid and vitamin are mixed with aqueous solution with the water for injection dissolving, be loaded on lyophilizing in freezer dryer in the container after the microporous filter, gland makes the vein water soluble vitamins.
7. preparation method according to claim 6 is characterized in that: add antiseptic, chelating agent and excipient in the aqueous solution of preparation, be loaded on lyophilizing in freezer dryer in the container then after the microporous filter, gland makes the vein water soluble vitamins.
8. vein as claimed in claim 1 is with the application in the medicine of water soluble vitamins vitimin supplement when preparation lacks because of the serious water soluble vitamins due to the disease, and consumption is intravenous drip every day 1～2 time, each one bottle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410005778 CN1251681C (en) | 2003-11-24 | 2004-02-20 | Highly concentration water-soluble vitamin for intravenous injection and preparation and use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200310111442 | 2003-11-24 | ||
| CN200310111442.5 | 2003-11-24 | ||
| CN 200410005778 CN1251681C (en) | 2003-11-24 | 2004-02-20 | Highly concentration water-soluble vitamin for intravenous injection and preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1543978A true CN1543978A (en) | 2004-11-10 |
| CN1251681C CN1251681C (en) | 2006-04-19 |
Family
ID=34378840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410005778 Expired - Fee Related CN1251681C (en) | 2003-11-24 | 2004-02-20 | Highly concentration water-soluble vitamin for intravenous injection and preparation and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1251681C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100361659C (en) * | 2005-01-12 | 2008-01-16 | 无锡凯夫制药有限公司 | Composite vitamin B powdery injection for venous infusion and preparation thereof |
| CN101259278B (en) * | 2008-04-21 | 2010-06-02 | 黄芝芳 | Optimum matching multiple water-soluble vitamin medicinal composition containing high-efficiency bacteriostat and preparation thereof |
| CN101961342A (en) * | 2010-08-19 | 2011-02-02 | 齐慧 | Water soluble vitamin composition for injection and preparation method thereof |
| CN102552294A (en) * | 2012-01-10 | 2012-07-11 | 辽宁海思科制药有限公司 | Compound vitamin (3) freeze-dried powder injection for injection and preparation method and analysis method thereof |
| CN104922142A (en) * | 2015-05-13 | 2015-09-23 | 邓学峰 | Pharmaceutical composition of water soluble vitamins and application of pharmaceutical composition |
-
2004
- 2004-02-20 CN CN 200410005778 patent/CN1251681C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100361659C (en) * | 2005-01-12 | 2008-01-16 | 无锡凯夫制药有限公司 | Composite vitamin B powdery injection for venous infusion and preparation thereof |
| CN101259278B (en) * | 2008-04-21 | 2010-06-02 | 黄芝芳 | Optimum matching multiple water-soluble vitamin medicinal composition containing high-efficiency bacteriostat and preparation thereof |
| CN101961342A (en) * | 2010-08-19 | 2011-02-02 | 齐慧 | Water soluble vitamin composition for injection and preparation method thereof |
| CN102552294A (en) * | 2012-01-10 | 2012-07-11 | 辽宁海思科制药有限公司 | Compound vitamin (3) freeze-dried powder injection for injection and preparation method and analysis method thereof |
| CN104922142A (en) * | 2015-05-13 | 2015-09-23 | 邓学峰 | Pharmaceutical composition of water soluble vitamins and application of pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1251681C (en) | 2006-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1709248A (en) | Lansoprazole lyophilized powder injection and its preparing method | |
| CN1543978A (en) | Highly concentration water-soluble vitamin for intravenous injection and preparation and use | |
| CN1931874A (en) | Prepn process, medicine prepn and medicinal use of ginseng glycopeptide | |
| CN1837200A (en) | Tanshinone I derivatives and pharmaceutical application thereof | |
| CN1671418A (en) | Oral administration of calcitonin | |
| CN1300175C (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN105582546B (en) | A kind of Entecavir phosphatide complexes and the compound enteric-coated tablet of diammonium glycyrrhizinate | |
| CN108904519A (en) | Hericium erinaceus Polysaccharides are in the purposes prepared in the drug for treating colitis and include its pharmaceutical composition | |
| CN1651433A (en) | Salviolic acid berberine double salt, its preparation method and application | |
| CN1895540A (en) | Medicinal composition for treating cardiovascular disease, its making method and use | |
| CN100464753C (en) | foscarnet sodium composition | |
| CN1555805A (en) | Ortho diphenylhydratoin freeze dried powder for injection and its preparation method | |
| CN1839920A (en) | Astragaloside injection and preparation method thereof | |
| CN1504191A (en) | Cucurbitacin lipsome preparation method and formulation | |
| CN1679914A (en) | Medicinal composition of induced glutathione and ebeselen | |
| CN1823904A (en) | Compound formula Chinese lobelia vein injection liquid, its preparation method and medicine infusion way | |
| CN1879687A (en) | An anti-tumor pharmaceutical composition and preparation method thereof | |
| CN1663600A (en) | Compound preparation composed of ginkgo leaf extracts and medicines promoting cerebral metabolism and its application | |
| CN109223764A (en) | DMXAA is preparing the application in hypoglycemic drug | |
| CN1283231C (en) | Orally disintegrating tablet and its preparation | |
| CN1706403A (en) | Self microemulsion of total dragon's blood flavone | |
| CN1526386A (en) | Houttuynin sodium powder injection and its prepn | |
| CN1872123A (en) | Medicine for treating virus hepatitis | |
| CN1454595A (en) | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver | |
| CN1518983A (en) | Coordinated modication combination for anti hepatitis B virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |